NOVO — Januar 2025

[UlrikChristiansen8]

hvad var konsensus får disse data?

[UlrikChristiansen8]

for*

[StockBull]

Fed nyhed, så starter de vel nok snart produktion i Kalundborg. Måske inden for kommende 12 mdr

[Sukkeralf]

fase 1/2 data

[ProinvestorNEWS]

Sydbank om Novo: Fuldstændig fair kursreaktion på stærke vægttabsdata https://proinvestor.com/investornyt/1269139/sydbank-om-novo-fuldstaendig-fair-kursreaktion-pa-staerke-vaegttabsdata

[ProinvestorNEWS]

Novos markedsværdi steg 183 mia. kr. efter stærke fedmedata https://proinvestor.com/investornyt/1269198/novos-markedsvaerdi-steg-183-mia-kr-efter-staerke-fedmedata

[koden]

endte "kun" 7% oppe

[JKY_VH]

jeg hæfter mig ved "vendingen" og 7% er ikke dårligt

[JKY_VH]

detalje, der "blot gør dagens nye resultater endnu mere imponerende." https://www.shareholders.dk/nyhed/novo-aktien-i-markant-stigning-efter-nye-data?utm_source=Aktionærens Nyhedsbrev&utm_campaign=be4509cbe1-20-07-2024_COPY_01&utm_medium=email&utm_term=0_bfc53fad21-be4509cbe1-90602917

[Helge_LarsenPI-redaktør]

Godmorgen

[Riis7]

godmorgen:_)

[Riis7]

[JKY_VH]

Tak Riis7

[Helge_LarsenPI-redaktør]

Novo Nordisk’s Amycretin: A Glimpse into the Future of GLP-1 Weight Loss Treatments https://www.onthepen.com/post/novo-nordisk-s-amycretin-a-glimpse-into-the-future-of-glp-1-weight-loss-treatments?utm_campaign=e6280513-1189-4af4-8ad5-bb1922b1e58a&utm_source=so&utm_medium=mail&cid=713e80cd-1fa6-468e-90d7-68fd62c5df0e

[koden]

Vi skal lige huske at studiet på Amycretin er et fase 1b/2a studie. Muligt de får lov at springe til fase 3. Men Cagrisema er vel stort set produktionsklar?

[Svend_Skriver]

'Virker usandsynligt, at Novo Nordisk rammes af potentiel toldsats, siger analytiker' Søren Løntofts vurdering. NB: Indslaget fra 22/1 2025.
https://nyheder.tv2.dk/live/udland/2025-01-18-trump-i-det-hvide-hus?entry=87246090-06e0-4e85-b939-4c550c316c73

[koden]

nej medmindre at trump vil presse DK om Grønland. Men de har jo brug for wegovy, så næppe.

[JKY_VH]

Fra Reuters "Veru said on Monday its
experimental drug, in combination with Novo Nordisk's
weight-loss treatment Wegovy, helped preserve muscle in older
patients with obesity, meeting the main goal of a mid-stage
study.
The study was testing Veru's oral drug, enobosarm, in
patients aged 60 and above. The drug targets androgen hormones,
which play a role in body development and reproductive health.
Patients who received the drug in combination with
Wegovy lost 71% less lean muscle on average than

[JKY_VH]

those who
received Wegovy alone, the company said."

[JKY_VH]

"Veru said on Monday its
experimental drug, in combination with Novo Nordisk's
weight-loss treatment Wegovy, helped preserve muscle in older
patients with obesity, meeting the main goal of a mid-stage
study."